13.12.2024
Proxima Research International is the first company to provide analytics of the pharmaceutical market of Uzbekistan, based on retail sales data from pharmacies (Sell Out), and not only shipments to the pharmacy (Sell In). Data on retail sales are implemented with a monthly discretion and are available both at the national level and in the context of various territories. Data from the analytical market research system ‘PharmXplorer’ of Proxima Research International were used in the preparation of the material.
According to the results of 9 months of 2024, the retail sales of drugs volume in the Republic of Uzbekistan amounted to 17.3 trillion soums, which in dollar terms corresponds to 1.4 billion dollars. In physical terms, the volume of retail consumption is 442 million packages. Compared to the same period of the previous year, the market volume increased by 15.7% in national currency and by 6.2% in dollar terms. In packages, consumption shows a decrease of 9.9%. In monthly dynamics, peak growth rates were recorded in January, May and July (Fig. 1).
Figure 1. Monthly dynamics of drugs pharmacy sales in Uzbekistan from January 2023 to September 2024
The top 3 marketing organizations in terms of drugs pharmacy sales at the end of September 2024 are formed by KRKA, Stada and Yuria-Pharm (Fig. 2). It should be noted that almost all companies that entered the top 20 showed double-digit growth rates. In most cases, the main contribution to the increase in sales is provided by price increases (as reflected by the inflation index).
Figure 2. Top 20 marketing organizations in terms of drugs sales in monetary terms at the end of September 2024
In a similar rating of international nonproprietary names (INN) of drugs, the combination of potassium chloride + calcium chloride + magnesium chloride + sodium lactate + sodium chloride + sorbitol is in the lead. The top 3 is closed by sodium arginine chloride.
Figure 3. Top 20 INNs in terms of sales in monetary terms at the end of September 2024
Meaningful proportion of sales is provided by antibacterial agents for systemic use (group J01ATC classification level 2), blood substitutes and perfusion solutions (B05) and anti-inflammatory and antirheumatic drugs (M01). In total, they accumulate 23.9% of drug sales in September 2024 (Fig. 4).
Figure 4. Top 20 groups of ATC-classification drugs of the 2nd level by pharmacy sales in monetary terms at the end of September 2024
Among the brands of medicines, the largest sales volume was recorded for the brands Rheosorbilact, Sodium chloride and Tivortin (Fig. 5).
Figure 5. Top 10 brands of medicines in terms of sales in monetary terms at the end of September 2024
Pharmacy sales in the context of regions differ significantly depending on the size of the population and the economic development of the region. The largest share of drug sales — 31.4% in monetary terms according to data for September 2024 — falls on the city of Tashkent (Fig. 6).
Figure 6. Regional distribution of pharmacy sales of drugs products in September 2024
According to the results of 9 months of 2024, the retail consumption market of drugs in the Republic of Uzbekistan shows the significant increase in monetary terms, while a decline is recorded in packages, which indicates the inflation impact and higher prices for drugs. Most of the top 20 marketing organizations by sales in September 2024 increased sales volumes at double-digit growth rates. The considerable share of sales falls on antibacterial agents for system use, blood substitutes and perfusion solutions, as well as anti-inflammatory and antirheumatic drugs.
The regional structure indicates the heterogeneous of the distribution of the pharmaceutical market. The largest sales volumes were recorded in the city of Tashkent, the capital and largest city of the Republic of Uzbekistan, which is probably due to its economic status and population.
Learn more about the capabilities of the Market Audit product from Proxima Research. Order a presentation or demo version.
By clicking«Submit», you consent to receive email communications about Proxima Research products and services and agree to our Terms of Use. Your data will be processed in accordance with our Privacy Police. You may opt-out at any time.
or
